The Week in Review: Feds: Even Those Sold It Did Not Know Contents of SGF-1000

This past summer, Michael Kegley Jr. and Kristian Rhein both pled guilty to felony drug adulteration and misbranding charges in the alleged international Thoroughbred doping conspiracy case. That means they'll avoid trials prior to their sentencings. But it doesn't mean that the voluminous cache of evidence that prosecutors would have used against them won't ever see the light of day.

In fact, just last week, the feds disclosed intriguing documentation about SGF-1000, the adulterated and misbranded purportedly performance-enhancing drug (PED) that was an elixir of choice for now-barred trainer Jorge Navarro, who admitted to injecting it into his horses when he pled guilty in August to one felony drug count. SGF-1000 allegedly also served as “juice” for fellow ruled-off conditioner Jason Servis, but he's still fighting his felony doping charges, even after being implicated by other defendants and allegedly being caught on intercepted phone calls discussing his wide-ranging use of PEDs.

The new intel about SGF-1000 arrived Nov. 15 in the form of a sentencing report for Kegley submitted by the government in advance of his Jan. 6 appearance in United States District Court (Southern District of New York), when he will learn his potential prison fate.

Both Kegley and Rhein are facing maximum three-year terms of incarceration. Rhein's sentencing is Jan. 5, and his report from the government is due Nov. 24.

Kegley is the former sales director for MediVet Equine, the Kentucky-based company that marketed and sold SGF-1000. Rhein is a now-suspended veterinarian formerly based at Belmont Park who has admitted that he and Servis were “leaders and organizers” of a network of associates who performed criminal actions related to doping. The feds also allegedly have Rhein taped on an intercepted phone call bragging that he sold “assloads” of SGF-1000 to racetrackers.

Soon after the arrests of 27 defendants on Mar. 9, 2020, we learned about Servis's alleged conversations with Rhein from June 2019 in which the trainer expressed fears that his purportedly doped MGISW Maximum Security would trigger a positive for SGF-1000. Rhein assured him Max wouldn't, because “they don't even have a test for it in America.”

And this past September, when prosecutors released a separate trove of wiretapped evidence, it was further disclosed that MediVet later in 2019 allegedly attempted to trick the Racing Medication and Testing Consortium (RMTC) into delisting SGF-1000 as a prohibited substance.

The government's sentencing submission from Nov. 15 fills in some previously unknown blanks about how SGF-1000 was marketed, pitched, and positioned during this time frame to maximize sales and avoid scrutiny.

$200 a bottle…but it worked

By the time SGF-1000 had landed in the crosshairs of federal prosecutors in early 2019, MediVet had already “reaped millions of dollars in revenue,” the court document stated. Part of the reason the company was able to rake in enormous profits had to do with bypassing the costs of the rigorous drug approval and registration process required by the Food and Drug Administration (FDA).

“Unlike legitimate drug manufacturers, MediVet spent no funds on studies to demonstrate to the FDA the safety and efficacy of SGF-1000,” the submission stated.

Working in tandem, Kegley and Rhein “both extolled the performance-enhancing benefits of the drug to racehorse trainers.”

Up until the spring of 2019, marketing material for SGF-1000 was routinely provided to purchasers and was readily available on MediVet's website. According to the government, its sellers emphasized “the potent effects of SGF-1000,” which were supposedly derived from “an innovative formulation consisting of Regenerative Proteins, Cytokines, Peptides, potent Growth Factors and Signaling Molecules derived from Ovine Placental Extract.”

The submission further stated that SGF-1000 was explained to trainers as being similar to a vasodilator that would “increase stamina, performance, and overall health.” The materials even listed the growth factors that were purportedly found in SGF-1000, including fibroblast growth factor and hepatocyte growth factor.

“Of course, many jurisdictions prohibited the use of such growth factors on racehorses, particularly where the growth factors are component parts of drugs that are not approved by the FDA, and administered solely to improve a horse's recovery and race performance,” the submission stated.

“Despite the advertised effects of, and ingredients in SGF-1000, the drug's appeal was rooted in the fact that it was undetectable in a horse's system through standard drug screens used in the racing industry, which Rhein repeatedly touted when discussing the drug,” the document continued.

The feds also alleged that despite what Kegley, Rhein, and other MediVet representatives claimed when they were parroting the company's marketing materials, no one pushing the product really had any accurate idea of what was in it.

“Notably, Kegley and his coconspirators did not know the precise contents of SGF-1000 until at least in or about August 2019–years after MediVet had started marketing and selling the drug,” the submission stated. “But [they] believed that no matter the component parts of the drug, it would enhance a horse's performance.”

So too, apparently did trainers. That's why they shelled out $200 a bottle for SGF-1000.

After Servis phoned Rhein on June 5, 2019, to allegedly tell him that Maximum Security had received a dose of SGF-1000 right before an unannounced drug test, “Rhein grew concerned regarding the potential for regulatory scrutiny of SGF-1000, and shared this concern with others at MediVet,” the sentencing submission stated.

The filing continued: “A few weeks later, on July 9, 2019,  Rhein and others affiliated with MediVet convened a conference call in which they discussed the potential for increased scrutiny of the drug. During that call, a participant mentioned that the federal government had prosecuted a racehorse trainer, Murray Rojas, for doping horses, citing it as an example of a case where drug use on racehorses had been pursued by governmental authorities beyond state racing commissions.

“Following the drumbeat of events indicating heightened suspicion of SGF-1000, Rhein and Kegley strategized regarding the best way to divert people's attention away from SGF-1000.

Rather than cease their sales of that drug, Kegley and Rhein instead discussed how they could tweak the labeling of SGF-1000, so as to make it appear innocuous,” the sentencing submission stated.

“You're right, it might help to re-brand it,” the feds allegedly recorded Kegley saying on a wiretap. “We won't mention the word 'growth factor' in any way shape or form…. We can even put on the box, you know, 'dietary supplement for equine.' That way it's not–no one even has to question if it's FDA-approved or not. It's strictly a supplement.”

RMTC Trickery

By the summer of 2019, the push was on at MediVet to try and convince the RMTC that this “supplement” was so harmless that it should be delisted as a banned substance.

“On August 8, 2019, a MediVet representative received a report from Industrial Laboratories reflecting a negative finding (at that time) for certain growth factors,” the court document stated.

Yet that same test did detect, among other prohibited substances, “low levels of acepromazine, levamisole, detomidine, pyrilamine, lidocaine, MEGX, xylazine, and caffeine.”

MediVet's reaction to this disturbing news?

According to the sentencing submission, it was “to request that the negative and positive findings be split into two separate reports. On Sept. 10, 2019, MediVet, through counsel, conveyed the negative findings to the RMTC, while withholding the positive findings.”

Around the same time, MediVet was feeling heat from regulators in New York who were zeroing in on SGF-1000 as an allegedly abused PED.

“In September 2019, MediVet's sales of SGF-1000 hit a significant hurdle,” the sentencing submission stated. “The New York Gaming Commission issued a notice in which it reiterated its longstanding prohibition against the use of growth factors and growth hormones on racehorses, but also specifically named SGF-1000 as a prohibited drug of the type that contained growth hormone or growth factors.”

Yet still, the court document explained, “Kegley and Rhein continued to market and sell SGF-1000” while MediVet “altered the promotional material for SGF-1000 to divert attention and mislead anyone who was unfamiliar with the prior marketing materials description of SGF-1000.”

So whereas the packaging and label for SGF-1000 in July 2019 described it as consisting of “regenerative placental proteins” and being “made in Australia,” by October the drug's description “had been altered to remove any reference to Australia, and was instead described as a 'homeopathic placental extract.'”

Yet by Oct. 14, 2019, MediVet had already learned “that a subsequent test of SGF-1000 did result in findings reflecting the presence of a specific growth factor,” the document stated.

And by the time Kegley and Rhein were arrested five months later, “the website for SGF-1000 had been scrubbed clean, removing any reference to growth factors, and much of the description regarding SGF-1000” itself.

“In short, even after Kegley and others at MediVet had reason to pause and take stock of the illegality of SGF-1000, they nonetheless continued to sell the drug,” the submission stated.

“With full knowledge that SGF-1000 was banned in New York, that a racehorse trainer had been criminally charged for doping, and that law enforcement was beginning to scrutinize the use of SGF-1000 specifically…Kegley and Rhein worked together and with others to deceptively label that drug, and to continue to sell the drug to those in the racehorse industry seeking a competitive advantage,” the document stated.

“Given the proliferation of websites that offer potent PEDs to those in the racehorse industry, similar to that operated by MediVet, a significant sentence is warranted to send a strong signal to others thinking of engaging in such criminality that there will be consequences for their crimes.

“Many actors in the racehorse industry have grown indifferent to, and dismissive of, the notion of obtaining illegal drugs to dope racehorses for profit, and assume that no serious ramifications will follow if they are ever caught,” the submission summed up.

The post The Week in Review: Feds: Even Those Sold It Did Not Know Contents of SGF-1000 appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

The Week in Review: Tygart, USADA Out to Clean Up the Game

We heard from the United States Anti-Doping Agency (USADA), its CEO Travis Tygart and the Director of Equine Science Dr. Tessa Muir last week when USADA released its anti-doping guidelines, rules and protocols. Once again, we saw that these are no-nonsense, dedicated people with a track record of cleaning up other sports. The release of the guidelines was an important step toward what will be a welcome change for racing–competent, dedicated policing from an outside entity replacing the current system, which just doesn't work.

(Quotes from this story were taken from Tygart and Muir's appearance on the TDN Writers' Room podcast and from Dan Ross's coverage in the TDN and his Q&A with Tygart and Muir.)

With Thursday's release of the details, there was a lot to digest. Here's what resonated with me:

(*) USADA is not going to rely solely on drug testing, which has been proven to be a woefully inadequate way of catching cheaters. There are always a number of potent drugs out there that can't be detected by standard drug tests. USADA may not have all the tools, including wiretaps, that the FBI had when it took down Jason Servis, Jorge Navarro and others, but Tygart made it clear that there are more ways to catch cheaters than just through drug tests.

“Can you bring a case if you don't have a positive test?” Tygart said. “In some states today, I don't think that's even possible under the rules. But if you look at Article Two of the rules, it identifies about 12 different types of violations. Only one or two of those includes a positive test. So possession, trafficking, complicity, attempted administration, retaliation against a whistleblower, those are things that can be anti-doping rule violations.”

He said that scientific evidence will be combined with “buckets of evidence”, much like what you see each week on shows like Law and Order and NCIS.

Tygart said they will also rely on a tip line that is already receiving calls. All of which is a step in the right direction. Neither Navarro nor Servis had any serious violations on their records that were the result of testing, which just goes to show that a lot more beyond testing needs to be done.

(*) USADA appears to understand the importance of going after more than just the trainers. It stands to reason that in most cases where performance-enhancing drugs are used, a veterinarian is involved. And what about the owners? It's hard to imagine they don't know what's going on when their trainer is wining at 30% and 50% off the claim. They should have to pay the price when their trainer is caught.

“When the horse is in training, the owner, the veterinarian, anyone else involved with the horse, they can be held accountable if they're complicit and part of a doping or a medication issue,” Tygart said. “The strict liability of the positive test doesn't apply to them. So there will be a slightly different way that this is prosecuted, but they absolutely can be held accountable under these rules.”

He added: “It's not just the trainer training the horse that has responsibility for this culture of a clean sport. Everybody within the sport should have a responsibility to ensure that it's being done the right way.”

(*) One thing that was not addressed last week was the obvious problem of having a trainer turn the stable over to an assistant once they are suspended. Life goes on largely uninterrupted for that stable with the head trainer getting what amounts to a vacation. There's not nearly enough of a deterrent here. At least with the more serious violations, the stable should be penalized along with a guilty trainer.

(*) USADA is going to rely heavily on out-of-competition testing and trainers must let USADA know at all times where a horse is located. He also said that out-of-competition tests won't be done on a random basis. For obvious reasons, the focus will be on trainers whose results suggest they might be using something to get an edge.

“It's what we call intelligent testing,” Tygart said. “It's not random. Some call it smart testing. Some call it target testing. We will use data.”

(*) You might want to call this one the “Baffert Rule.” While USADA will distinguish between violations that involve performance-enhancing drugs and overages of therapeutic medications, Tygart believes that there is a point where enough is enough when it comes to overages. Four minor infractions or therapeutic overages within five years could result in a sanction of up to two years.

(*) Just because a horse passes post-race urine and blood tests doesn't mean that they can't be caught later on. If someone uses something illegal and a new test for that substance comes around after the fact, they could get nailed. This is another welcome development.

“We will have the ability to do what is called retrospective testing,” Tygart said. “Samples will be put into storage. And then when you develop new tests in the future, we're going to be able to bring those samples out of storage and actually then analyze them with the new methodology for those prohibited old-time substances. That's also a great deterrent to people using things where they say you can't detect it. But in the future, when those technologies and the capabilities are enhanced and changed, then we can go back and you will still be subject to sanction (for a positive test).”

(*) More than six months after the race, the Kentucky Horse Racing Commission has still not acted when it comes to this year's GI Kentucky Derby and the reported betamethasone positive on winner Medina Spirit (Protonico). That, Tygart said, will not happen after USADA takes over.

“I was pretty stunned to hear that (Medina Spirit's) Kentucky Derby case hasn't been resolved yet,” Tygart said. “That's not going to happen on our watch. I mean, it's crazy that it's taken that long to get to a final resolution, particularly when someone is competing the entire time.”

Lawsuits have been filed by horsemen's groups and six states to shoot down the Horseracing Safety and Integrity Act (HISA), which is what created the need for a new method of policing the sport, and USADA has yet to sign a contract with the Horseracing Integrity and Safety Authority. Both factors could mean that the projected start date for HISA, July 1, 2022 will not be met.

But if and when HISA goes into effect, USADA will be ready. Tygart called the new rules a “gold standard program for the industry.” He's got that right. It's time for a new era.

The post The Week in Review: Tygart, USADA Out to Clean Up the Game appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Judge Dismisses Motions To Suppress Wiretap Evidence In Federal Case, First Trial Date Set

Evidence gathered by the FBI, including wiretaps, may be used at trial against the trainers, veterinarians, and others charged with federal drug adulteration and misbranding. U.S. District Court Judge Mary Kay Vsykocil made the ruling at an in-person hearing conducted Nov. 4. The judge has not yet filed a full legal opinion detailing her reasoning for denying the motions, which alleged the FBI had attained the wiretaps using misleading information on its application.

Several defendants, including trainer Jason Servis, had filed their own motions to suppress or joined together on existing motions. Motions from Jordan Fishman, Marcos Zulueta, and Christopher Oakes had been withdrawn when those defendants entered guilty pleas in recent weeks.

Judge Vyskocil also moved forward with trial scheduling. Attorneys had already agreed that the remaining defendants would be clustered in three groupings for trial purposes, according to who seemed to have worked together in the relevant, alleged criminal activities. The first group will consist of Dr. Seth Fishman, who is accused of making a number of performance-enhancing substances, and Lisa Giannelli, who is accused of helping to distribute those products. An order from the judge entered Nov. 4 stated the first trial is expected to begin on or about Jan. 19, 2022.

Defendants in the second group could see a trial toward the latter part of the first quarter of 2022, though a date range was not included in the Nov. 4 order. That grouping includes Rick Dane Jr. and Dr. Rebecca Linke.

The remaining defendants include Dr. Erica Garcia, Jason Servis, Michael Tannuzzo, and Dr. Alex Chan. Prosecutors have expressed a desire to try those four defendants together, although the judge left the door open this week that she may hear severance motions if any of the defendants move to be tried separately.

The next status conference in the case is scheduled for Jan. 13, 2022.

The post Judge Dismisses Motions To Suppress Wiretap Evidence In Federal Case, First Trial Date Set appeared first on Horse Racing News | Paulick Report.

Source of original post

Trial Groupings Reset for Defendants in Alleged Doping Conspiracy

In the wake of nine defendants in the alleged nationwide horse-doping conspiracy case having changed their pleas to “guilty” in recent months, a Nov. 4 status hearing reset the trial groupings for the remaining defendants, with those trials all now anticipated to commence in the first half of 2022.

Judge Mary Kay Vyskocil of United States District Court (Southern District of New York) also ordered that all remaining motions to suppress evidence that are pending on the docket are to be considered denied, noting that her written opinion on that decision is forthcoming.
Trial Group I shall now consist of defendants Seth Fishman and Lisa Gianelli. They had been previously advised their trial will commence on or about Jan. 19, 2022.

Group II shall consist of defendants Rick Dane Jr. and Rebecca Linke. On Thursday, the judge told them to expect to face a trial in the latter part of the first quarter of 2022.

Group III defendants Jason Servis, Erica Garcia, Michael Tannuzzo and Alexander Chan will be tried together at a date that has not yet been set. On Thursday, the judge ordered the prosecution and defense attorneys to get together over the next week to hash out a proposed schedule for the filing of related briefs, after which a trial date can be established by the court.

The now-barred trainers Servis and Jorge Navarro are the two highest-profile defendants in the case.

Navarro has already pled guilty to one count of conspiring to administer non-FDA-approved, misbranded and adulterated drugs, including PEDs that Navarro believed would be untestable and undetectable.

Navarro faces five years in prison at his December sentencing, and has admitted in open court that he doped the now-deceased elite sprinter X Y Jet and other graded stakes stars of his stable over a period of years. Navarro's plea deal also stipulates that he must pay $25.8 million to a list of victims that has not yet been made public.

Servis was the trainer of the former $16,000 maiden-claimer Maximum Security, who crossed the wire first in the 2019 GI Kentucky Derby but was disqualified for interference.

As evidence against Servis's alleged felonies, the feds have purportedly recorded him in numerous wiretapped phone conversations discussing with Navarro the doping regimens of top horses in his care, including administering injections of PEDs to Maximum Security.

The post Trial Groupings Reset for Defendants in Alleged Doping Conspiracy appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights